Sara Baglivo

Dr. Sara Baglivo

Azienda Ospedaliera di Perugia
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2018 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
BRBiagio Ricciuti
Biagio Ricciuti
CGCarlo Genova
Carlo Genova
Andrea De GiglioAndrea De Giglio
Andrea De Giglio
MBMaria Bassanelli
Maria Bassanelli
MBMARIA GIOVANNA DAL BELLO
MARIA GIOVANNA DAL BELLO
RCRita Chiari
Rita Chiari

1 April 2019 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
BRBiagio Ricciuti
Biagio Ricciuti
GLGiulia Costanza Leonardi
Giulia Costanza Leonardi
PPPaolo Puccetti
Paolo Puccetti
Francesca FallarinoFrancesca Fallarino
Francesca Fallarino
VBVanessa Bianconi
Vanessa Bianconi
Matteo PirroMatteo Pirro
Matteo Pirro

Verified
Journal Article
Open access
PDF file
MCMatteo Canale
Matteo Canale
EPElisabetta Petracci
Elisabetta Petracci
ADAngelo Delmonte
Angelo Delmonte
GBGiuseppe Bronte
Giuseppe Bronte
ECElisa Chiadini
Elisa Chiadini
Paola UliviPaola Ulivi
Paola Ulivi
Background: Non-small cell lung cancer (NSCLC) is the primary cause of cancer-related deaths worldwide. Epidermal Growth Factor Receptor (EGFR)-mutated patients usually benefit from TKIs treatment, but a significant portion show unresponsiveness due to primary resistance mechanisms. We investigated the role of TP53 mutations in predicting survival and response to EGFR-TKIs in EGFR-mutated NSCLC patients, to confirm, on an independent case series, our previous results. Methods: An independent retrospective cohort study was conducted, on a case series of 136 EGFR-mutated NSCLC patients receiving first or second generation TKIs as a first line therapy, and a smaller fraction of patients who acquired the T790M resistance mutation and were treated with third generation TKIs in the second or further line of treatment. TP53 mutations were evaluated in relation to disease control rate (DCR), objective response rate (ORR), progression-free survival (PFS) and overall survival (OS) of the patients. Results: Forty-two patients (30.9%) showed a TP53 mutation. Considered together, TP53 mutations had no significant impact on time-to-event endpoints. Considering the different TP53 mutations separately, exon 8 mutations confirmed their negative effect on PFS (HR 3.16, 95% 1.59–6.28, p = 0.001). In patients who developed the T790M resistance mutation, treated with third generation TKIs, the TP53 exon 8 mutations predicted worse PFS (even though not statistically significant), and OS (HR 4.86, 95% CI: 1.25–18.90, p = 0.023). Conclusions: TP53 exon 8 mutations confirmed their negative prognostic impact in patients treated with first and second generation TKIs and demonstrated a role in affecting clinical outcome in patients treated with third generation TKIs.

Verified
Journal Article
Open access
PDF file
MMMartina Mandarano
Martina Mandarano
EOElena Orecchini
Elena Orecchini
GBGuido Bellezza
Guido Bellezza
Jacopo VannucciJacopo Vannucci
Jacopo Vannucci
VLVienna Ludovini
Vienna Ludovini
MBMaria Laura Belladonna
Maria Laura Belladonna
The enzyme indoleamine 2,3-dioxygenase 1 (IDO1) degrade tryptophan (Trp) into kynurenine (Kyn) at the initial step of an enzymatic pathway affecting T cell proliferation. IDO1 is highly expressed in various cancer types and associated with poor prognosis. Nevertheless, the serum Kyn/Trp concentration ratio has been suggested as a marker of cancer-associated immune suppression. We measured Kyn and Trp in blood samples of a wide cohort of non-small-cell lung cancer (NSCLC) patients, before they underwent surgery, and analyzed possible correlations of the Kyn/Trp ratio with either IDO1 expression or clinical–pathological parameters. Low Kyn/Trp significantly correlated with low IDO1 expression and never-smoker patients; while high Kyn/Trp was significantly associated with older (≥68 years) patients, advanced tumor stage, and squamous cell carcinoma (Sqcc), rather than the adenocarcinoma (Adc) histotype. Moreover, high Kyn/Trp was associated, among the Adc group, with higher tumor stages (II and III), and, among the Sqcc group, with a high density of tumor-infiltrating lymphocytes. A trend correlating the high Kyn/Trp ratio with the probability of recurrences from NSCLC was also found. In conclusion, high serum Kyn/Trp ratio, associated with clinical and histopathological parameters, may serve as a serum biomarker to optimize risk stratification and therapy of NSCLC patients.

17 November 2015 in Expert Review of Respiratory Medicine
Verified
Journal Article
Closed access
BRBiagio Ricciuti
Biagio Ricciuti
GLGiulia Costanza Leonardi
Giulia Costanza Leonardi
GMGiulio Metro
Giulio Metro
FGFrancesco Grignani
Francesco Grignani
LPLuca Paglialunga
Luca Paglialunga
LCLucio Crinò
Lucio Crinò
Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. . ???aop.label???. doi: 10.1586/17476348.2016.1115349

1 March 2015 in Lung Cancer
Verified
Journal Article
Closed access
DIDaniela Iacono
Daniela Iacono
RCRita Chiari
Rita Chiari
GMGiulio Metro
Giulio Metro
CBChiara Bennati
Chiara Bennati
GBGuido Bellezza
Guido Bellezza
LCLucio Crinò
Lucio Crinò